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Abstract
Food allergy is a major public health problem for which there is no effective treatment. We
examined the immunological changes that occurred in a group of children with significant cow’s
milk allergy undergoing a novel and rapid high dose oral desensitization protocol enabled by
treatment with omalizumab (anti-IgE mAb). Within a week of treatment, the CD4+ T cell response
to milk was nearly eliminated, suggesting anergy in, or deletion of, milk-specific CD4+ T cells.
Over the following three months while the subjects remained on high doses of daily oral milk, the
CD4+ T cell response returned, characterized by a shift from IL-4 to IFN-γ production.
Desensitization was also associated with reduction in milk-specific IgE and a 15-fold increase in
milk-specific IgG4. These studies suggest that high dose oral allergen desensitization may be
associated with deletion of allergen-specific T cells, without the apparent development of allergen-
specific Foxp3+ regulatory T cells.
Introduction
Although allergen desensitization in patients allergic to environmental agents such as
pollens, dust mite, or cat dander has been performed for more than 100 years 1, the precise
immunological mechanisms of allergen desensitization remain controversial. The
development of blocking IgG antibody was initially thought to play an important role in
mediating the allergen desensitization and tolerance processes 2. However, other
mechanisms such as immune suppression, mediated by allergen-specific adaptive regulatory
T (TReg) cells, have received intense investigation as the cell type that accounts for the
success of immunotherapy 3–6. The development of allergen-specific Foxp3+ TReg cells
during desensitization with inhalant allergen or bee venom is consistent with the idea that
tolerance induced with low antigen doses (microgram amounts), such as those used in
subcutaneous desensitization protocols, is associated with the development of allergen-
specific TReg cells 7.
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tProtocols for oral allergen desensitization in patients with immunoglobulin (Ig)E-mediated
food allergy are currently being developed, but little is known about the mechanisms of oral
desensitization, during which high doses (gram amounts) of oral antigen are generally
administered. In mouse models of oral tolerance, administration of high doses of oral
antigen in naïve animals is associated with the development of anergy and deletion of
antigen-specific T cells, whereas administration of low doses of oral antigen is associated
with TReg cell development 8. On the other hand, much less is known about the mechanisms
of oral desensitization in the setting of established allergy in humans.
In humans, the examination of the immunological mechanisms of oral desensitization for
food allergy has been hampered by several problems. First, unpredictable allergic reactions
in patients have resulted in desensitization courses that vary from months to years. In
addition, food-specific T cells, which constitute a very small fraction (<1%) of peripheral T
cells, are difficult to study, and have been examined primarily via bulk population
activation, or by cloning (or establishing cell lines), which typically involves several cycles
of antigen stimulation with exogenous cytokines 9–11, although in some studies, peanut
specific T cells were examined more directly using a dye dilution method 12, 13.
Nevertheless, studies of oral food desensitization consistently demonstrate a decrease in
allergen-specific IgE and an increase in allergen-specific IgG4, suggesting that oral
desensitization induces allergen-specific immune deviation 14–18.
To better understand the immunological changes that occur during oral food desensitization,
we examined a small cohort of children with IgE-mediated milk allergy in a clinical trial of
oral cow’s milk desensitization performed in combination with a 16-week course of
omalizumab (anti-IgE monoclonal antibodies, Xolair). The oral desensitization protocol,
which was the first to use omalizumab to limit allergic reactions, allowed patients to be
rapidly (over a 7–11 week period of time) desensitized to high doses of milk with a uniform
dosing schedule. The clinical findings of this study, showing that 10 of the 11 patients with
significant milk allergy were desensitized, have been briefly described elsewhere 19. Herein,
we describe the dynamic milk-specific immunological changes that occurred in these
patients, analyzed in several subgroups of patients, over the course of the oral milk
desensitization protocol.
Results
All subjects in the clinical trial began treatment with omalizumab at week 0, and started oral
desensitization with milk at week 9 19. 12 doses of milk were given on the first day of
desensitization, increasing from 0.1 mg to 1,000 mg every 30 minutes (cumulative dose on
the first day, 2,000 mg milk protein). The patients then continued on a daily dose of milk
(1,000 mg/day), which increased every 7 days until a dose of 2,000 mg milk/day was
achieved. At week 16, the omalizumab was discontinued, but patients remained on a daily
dose (2,000 mg/day) of milk. At week 24, nine of the 10 patients remaining in the study
passed a double blind food challenge and began taking >8,000 mg of milk per day.
Milk-induced CD4 T cell proliferation is reduced during rush desensitization
Peripheral blood mononuclear cells (PBMC) from a subset of 5 patients were isolated at
multiple time points during the desensitization protocol (weeks 0, 9, 10, 12, 14, 16, 24, 30,
36 and 52), and frozen in aliquots in liquid nitrogen for later examination. To characterize
the response to milk, PBMC from multiple time points for each patient were thawed, labeled
with carboxyfluorescein succinimidyl ester (CFSE) and cultured in the presence of milk
proteins (MP) (or tetanus toxoid (TT)) for 7 days. In all patients examined, there was a
vigorous proliferative response to milk proteins (and TT) at week 0, as demonstrated by
flow cytometry, which showed a significant number of CD4+ T cells with low levels of
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tCFSE, representing cells that underwent multiple cell divisions (Figure 1a) (mean milk-
specific CD4+ T cells=7.75%; mean tetanus-specific cells=24.6%; mean, no
antigen=0.62%). However, a striking decrease in milk-specific CD4+ T cell proliferation
was observed 1 week after initiation of desensitization in all 5 patients examined, which
persisted as the daily dose of milk increased (during weeks 8 to 16) (Figures 1b and c). This
effect was specific for the milk-induced response, and was not observed with the TT
response. Importantly, the response to milk returned over the ensuing 3–4 months, while the
subjects remained on daily oral milk. Although omalizumab treatment was stopped at week
16 and coincided with the increase in milk specific proliferation, there was no appreciable
change in the tetanus toxoid response.
Absence of functional milk specific TReg cells during the desensitization
We examined possible mechanisms for the initial transient reduction in the milk-specific
proliferative response. Surprisingly, we found no evidence for an increase in the number of
milk-specific TReg cells (CFSElow CD4+ Foxp3+) in the cultures stimulated with milk
proteins (Figure 2a). Since TReg cells may not proliferate, we also examined CFSEhigh (non-
proliferating cells) and found no increase in the number of CD4+ Foxp3+ TReg cells (Figure
2b and c). Furthermore, we showed that IL-10 secreting suppressive/regulatory T cells were
not responsible for the reduced proliferation, since no increase in milk-induced CD4+ T cell
proliferation was observed in the presence of anti-IL-10 mAb (Figure 3a). Moreover,
addition of anti-10 and anti-TGF-β (5 μg/ml) mAb together did not increase the milk-
induced proliferative response at any time point, indicating that IL-10/TGF-β producing
regulatory T cells were not responsible for the reduction in the response to milk (data for
week 12, Figure 3b). Finally, we performed mixing experiments, in which purified CD4+ T
cells or CD4+ CD25+ T (TReg) cells from PBMC collected at weeks 12 and 14, when the
proliferative response was low, were cultured with PBMC from week 0. In these
experiments, milk-induced proliferation was assessed by [3H]-thymidine incorporation
during the last 16 hours of a 6-day culture. Neither CD4+ T cells nor CD4+ CD25+ cells
were able to reduce the week 0 PBMC response to milk (Figure 3c). Together, these results
suggest that Treg cells were not involved in the reduction of the milk-specific CD4+ T cell
proliferation observed during desensitization at weeks 10–14.
Evidence for milk specific T cell anergy
We next examined whether anergy, defined by lack of responsiveness to antigen that can be
restored with IL-2 and associated with the absence of suppressive activity 20, could explain
the reduced milk-specific T cell proliferative response. First, treatment of milk-activated
CD4+ T cells isolated at week 12 with IL-2 partially restored the proliferation of milk-
specific CD4+ T cells, although this increase only trended towards statistical significance
(p=0.07) (Figure 4a). Furthermore, we found that during the initial desensitization period
(weeks 10 and 16), the limited number of CD4+ T cells responding to milk expressed lower
levels of CD25 (an activation antigen) compared to that at week 0 (Figure 4b), suggesting
that the milk-specific cells at these time points could not be fully activated. In contrast, milk-
specific T cells from patient #3, who was only partially desensitized (reacted at the 1,000 mg
dose during the double blind placebo controlled food challenge (DBPCFC) at week 24), and
who had less of a reduction in milk-induced proliferation at week 10 (Figure 1c), had no
reduction in CD25 expression at weeks 10 and 16 compared to week 0 (Figure 4c and d).
Moreover, in the one patient in whom PD-1, an antigen expressed by anergic or exhausted T
cells 21, 22, was examined (patient #5, who was successfully desensitized), we found that
milk-specific CD4+ T cells expressed a significant increase in PD-1 at weeks 10 and 16 (as
well as reduced levels of CD25) compared to week 0 (Supplementary Figure S1). These
results together suggest that anergy could, at least in part, explain the reduction of milk-
specific CD4+ T cell proliferation observed after the rush desensitization phase.
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tEvidence for immune deviation during milk desensitization
While the cytokine profile of the milk-specific CFSElow CD4+ T cells did not change
appreciably during the first 30 weeks, the ratio of IFN-γ/IL-4 production of the milk-
specific T cells increased substantially between weeks 36 and 52 (Figure 5a). This increase
in the IFN-γ/IL-4 ratio was observed in patients who passed the DBPCFC and were fully
desensitized (Figures 5b and c), but was delayed for patient #3 who was only partially
desensitized (Figure 5b). IL-13 production in the milk specific CD4+ T cells was examined
in one patient (#5), and found to follow IL-4 production, in that the IFN-γ/IL-13 ratio
increased after week 30 (Figure 5d). The increase in the IFN-γ/IL-4 ratio in the milk-
specific CD4+ T cells suggests that immune deviation developed late during the
desensitization, consistent with the significant reduction in milk-specific IgE at weeks 36
and 52 observed in all 10 patients examined (Figure 5e), and by a 15 fold increase in milk-
specific IgG4 seen after week 24 in all 10 patients (Figure 5f).
Milk specific basophil activation is reduced by milk desensitization
On enrollment, all 10 patients who completed the study had significant immediate skin
reactivity to milk (week 0). However, by week 52 of the study, immediate skin prick test
responses to cow’s milk were reduced compared week 0 in 9 of the 10 patients (p<0.01)
(Figure 6a). In contrast, there was no statistically significant change in immediate skin
testing to other allergens (cashew or egg) at week 52 compared to week 0, in the four
patients who were skin tested to these other allergens (Figure 6b).
Similarly, in in vitro studies, we found that cow’s milk antigen, but not vehicle, activated
peripheral blood basophils taken on enrollment (week 0), as demonstrated by an increase in
basophil expression of CD203c and CD63 (basophil activation markers); in histamine
release (p<0.001) (Figure 6c); and in phospho-Syk expression, Supplementary Figure S2).
However, treatment of the patients with omalizumab, beginning on week 0 and continuing
through week16, greatly reduced milk-induced basophil activation (Figure 6c,
Supplementary Figure S2, weeks 8–16). Importantly, the reduction in milk-induced basophil
activation persisted after omalizumab was discontinued (weeks 24–52), presumably
reflecting a milk-desensitized state, and consistent with the reduction of milk-specific skin
test reactivity at week 52 and reduced milk-specific IgE at weeks 36 and 52. The reduction
in milk-induced basophil activation at weeks 24–52 was antigen specific, since egg and
cashew antigens activated the basophils obtained at weeks 24–52, after discontinuation of
omalizumab treatment, as demonstrated by increased antigen-induced expression of
CD203c, CD63, increase in histamine release (Figure 6d); and increase in phospho-Syk
expression (Supplementary Figure S2). The basophil response to egg and cashew at weeks
24–52 were not quite as robust as at week 0, but were clearly much greater than the very
limited basophil responses observed at weeks 8–16, when the patients were being treated
with omalizumab. These results together indicated that the mast cell compartment (i.e., mast
cells in the skin and basophils in the peripheral blood) was greatly inhibited in an allergen-
non-specific fashion during omalizumab treatment, and in an antigen-specific fashion after
completion of the oral milk desensitization protocol.
Discussion
Food allergy is a major public health problem that has increased dramatically in prevalence
in industrialized countries over the past 10 to 15 years 23, 24. Unfortunately for patients with
food allergy, there is no effective treatment except to avoid the offending foods, and to have
ready access to self-injectable epinephrine 25. Recently however, several reports indicate
that oral desensitization may be effective in patients with allergy to several different foods,
including milk, egg, peanut and hazelnut 14–18, 26–30. The protocols for desensitization are
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tdiverse, and even with a given protocol, the pace at which the dose of allergen increases
varies considerably between patients, due to unpredictable allergic reactions, which
confounds the analysis of mechanisms that mediate oral desensitization. As a result, the
mechanisms of oral desensitization in patients with food allergy are poorly understood.
In this study, we examined the mechanisms of oral desensitization in a small group of
children, who tolerated a novel, relatively rapid and uniform, presumably high dose oral
desensitization protocol, enabled with omalizumab, which was used in this setting for the
first time 19. After stopping omalizumab, 9 of the children added normal amounts of milk
(>8–12 g/day, equivalent to >240–360 ml/day) to their diets 15 to 19 weeks after starting the
oral desensitization, and the 10th child was able to consume 1–2 g of milk daily by week 52.
Because enrollment in this study was restricted to children with high levels of serum milk-
specific IgE (median milk-specific IgE 50 kUA/L, mean 98 kUA/L)), which are associated
with milk allergy that is less likely to resolve 31, we believe that the immunological changes
observed in these patients are highly significant.
Using CFSE labeling of PBMC in our analysis, we focused on milk-specific CD4+ T cells
and found that prior to desensitization, the milk-specific CD4+ T cells were T helper (Th)2-
skewed, as expected 9, 11, 12, but that rapid high dose allergen administration greatly but
temporarily decreased milk-induced, but not tetanus-induced, CD4+ T cell proliferation.
Surprisingly, the acute reduction in milk-specific T cell proliferation in the patients
examined was not associated with the development of allergen-specific Foxp3+ TReg cells,
nor was there evidence of suppression, as shown by coculture experiments. Moreover, the
reduction in milk-specific CD4+ T cell proliferation that occurred during the rapid
desensitization period could be partially reversed with the addition of IL-2 to the cultures.
This suggested that high dose milk administration resulted initially in the development of
milk-specific CD4+ T cell anergy and possibly deletion 18, although additional studies must
be performed to fully understand the mechanisms of high dose oral desensitization,
particularly because of the limited number of patients analyzed.
Rapid reductions in allergen-specific CD4+ T cell responses have been previously observed
in beekeepers exposed to multiple bee stings due to the development of venom specific TReg
cells 7. In these subjects, venom-specific IL-10-producing TReg cells developed with
repeated bee stings (average cumulative antigen dose over 7 months was <1–4 mg).
Similarly, subcutaneous immunotherapy with grass pollen and bee venom, in which the
allergen doses are low, ranging from 4–100 μg/dose, as well as with cat allergen peptides,
induced allergen-specific tolerance associated with the development of allergen-specific
TReg cells producing IL-106, 32–35. There results are consistent with the idea that
administration of low doses of antigen during immunotherapy induces allergen-specific TReg
cells 8.
In contrast, in our study of oral desensitization, we used much higher doses of antigen (gram
amounts daily), and surprisingly, desensitization was not associated with IL-10 producing
milk-specific TReg cells. Furthermore, we failed to observe an increase in the number of
Foxp3+, natural TReg cells, which are thought to primarily prevent the development of
autoimmunity 36. Several studies have shown that the frequency of natural Foxp3+ CD4+
CD25+ TReg cells increased after peanut oral immunotherapy 37, 38, although this was not
observed in other studies 39–41. It is possible that in our patients, milk-specific TReg cells
and/or natural Foxp3+ CD4+ CD25+ TReg cells were present only in the gastrointestinal
tract, or could develop later, e.g., after 12–18 months of daily oral milk maintenance.
Alternatively, it is possible that milk-specific TReg cells develop only with low antigen
exposure, e.g., induced by exposure to small amounts of milk, and prior to ingestion of full
dietary quantities of milk 13.
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tIn our patients, after 4–6 months of daily high doses of oral milk, we found that a vigorous
milk-specific CD4+ T cell response returned, but still without evidence of milk-specific
Foxp3+ TReg cells. This robust milk-specific T cell response, associated with increased
production of IFN-γ, a 15 fold increase in milk-specific IgG4, as well as reduced milk-
specific IgE, suggested that high dose oral desensitization evolved into a form of immune
deviation. A similar Th1-like allergen-specific response was reported in peanut allergic
individuals who had naturally outgrown their sensitivity 12, and in milk-specific Peyer’s
patch T cells from non-allergic individuals 42. In those studies, like in our desensitized
subjects, the presence of food-specific Foxp3+ TReg cells was also not observed, suggesting
that high dose allergen-specific tolerance may not always be associated with allergen-
specific Foxp3+ TReg cells. However, is possible that the milk-specific CD4+ T cells
producing IFN-γ that we observed may exert inhibitory activity on IgE-mediated milk-
induced symptoms through unclear mechanisms 43, 44, particularly since milk-specific IgE
was still present after the desensitization in most of our patients. Alternatively, it is possible
that milk-specific IgG4 ay play a very dominant role in inhibiting IgE-mediated symptoms
and inflammation 3.
Currently, all of our subjects have fully completed the 52 week study, and remain on daily
oral milk to maintain their desensitized state. The patients continue to be followed, and over
time it is possible that a more permanent tolerant state may develop, such that the capacity to
tolerate milk may persist even after oral milk dosing is discontinued 45, perhaps indicating a
clinical “cure” of the allergy. However, based on the experience with subcutaneous
immunotherapy with inhalant allergens and bee venom, in which long-lived symptom
control and allergen “tolerance” is achieved only after completing 3–5 years of
“maintenance” therapy 46, 47, complete milk specific immunological “tolerance” may
require several years of frequent milk exposure. On the other hand, because the antigen
doses with oral desensitization are much greater than that of subcutaneous immunotherapy,
it is possible that immunological tolerance might develop sooner with oral immunotherapy,
as has been suggested 18, 48.
In summary, we examined milk-specific immune responses in a small number of patients
who completed a novel, rapid and uniform high dose oral milk immunotherapy protocol
enabled with omalizumab. Within a week of the initial rapid oral desensitization, we
observed an acute and significant reduction of milk-specific T cell responses, without
evidence of Foxp3+ TReg cell development, suggesting the induction of anergy in, or
deletion of, effector T cells. The reduced or anergic response was later replaced by a
vigorous CD4+ T cell response, characterized by a shift from IL-4 to greater IFN-γ
production, and associated with reduced milk-specific IgE production, reduced milk-specific
basophil degranulation, and increased milk-specific IgG4 production. Although our study
included a very small number of patients, and requires replication and confirmation in a
much larger patient population, the immunological changes observed in the desensitized
patients were surprisingly uniform and statistically significant. These results suggest that
rapid high dose oral desensitization induces allergen-specific immune deviation not
associated with Foxp3+ allergen-specific TReg cells, reminiscent of allergen-specific
immunity associated with the natural resolution of food allergy 12. In addition, these results
provide an improved understanding of high dose oral desensitization in humans, and could
lead to better therapies and diagnostic methods for patients with food allergies.
Methods
Study Population
Eleven patients with a history of significant IgE-mediated milk allergy (defined as having a
significant immediate reaction on accidental ingestion of milk, including generalized
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turticaria, vomiting and/or anaphylaxis) were enrolled in the study at two sites, the Children’s
Hospital Boston and at Stanford University School of Medicine. The subjects included 7
boys and 4 girls. 10 of 11 subjects had a past or current history of eczema, asthma, or both,
10 had a history of at least 1 other food allergy, and 6 had 2 or more additional food
allergies. The mean age of the patients was 10.2 years (median, 8, range 7–17 years), the
median milk-specific IgE was 50 kUA/L (mean 98, range 42 to 342 kUA/L) (normal <0.35)
(Phadia ImmunoCAP System), and the median skin prick test (SPT) wheal responses to milk
extract was 22 mm (mean 20, range 11–46 mm) 19. The institutional review boards of both
institutions approved the clinical protocols, and all participants and/or their parents provided
written informed consent. The trial was registered at www.clinicaltrials.gov
(NCT00968110).
Clinical protocol
Patients were pre-treated with omalizumab for 9 weeks, allowing IgE to detach from FcεR1
on the surface of mast cells and bind to omalizumab, before starting the oral desensitization
to cow’s milk 19. At week 9, the oral desensitization began with 0.1 mg of cow’s milk
protein (dried nonfat powdered milk, Carnation Instant Milk, Nestle) mixed in water. There
were 12 doses on the first day of desensitization (0.1, 0.5, 1.5, 3, 7, 15, 30, 60, 125, 250,
500, 1,000 mg) given every 30 minutes (cumulative dose 1,992 mg). One subject voluntarily
discontinued the study after the 5th oral dose due to vomiting, later diagnosed as abdominal
migraines. The day after the rush desensitization, patients returned to start the slower dose
escalation, build-up phase, and received the highest dose of milk achieved on the previous
day, up to 1,000 mg. Subjects received the same daily dose at home for the next 6 days. The
subjects returned weekly for an increase in the oral dose (increase of 12.5%) until a daily
oral dose of 2,000 mg was attained (over a period of 7–11 weeks). At week 16, omalizumab
treatment was discontinued, while daily oral milk continued. Treatment with omalizumab
was extended by 2–4 weeks in 2 of 10 remaining subjects, to allow the milk dose to increase
to 2,000 mg. At week 24 (8 weeks after discontinuing the omalizumab), a DBPCFC to milk
was conducted. The challenge consisted of 5 doses administered orally every 15 minutes:
500 mg, 750 mg, 1,000 mg, 2,000 mg and 3,000 mg (cumulative dose 7,250 mg). 9 of the 10
remaining subjects passed the DBPCFC, and an open challenge of 4,000–8,000 mg (120 –
240 ml) of milk was given 2–16 h later.
Patient samples
Blood was taken at multiple time points before, during and after the desensitization protocol
(week 0, 8, 9, 10, 12, 14, 16, 24, 30, 36 and 52). PBMC were isolated from the blood of 5
patients (at the Children’s Hospital Boston site) by density-gradient separation using
Histopaque-1077. The PBMC were frozen in aliquots and stored in liquid nitrogen for later
examination. In all experiments, PBMC aliquots from multiple time points for each patient
were thawed and studied together so that changes in the phenotype/function of the cells over
time could be assessed accurately. Fresh blood samples from 5 patients (at the Stanford site)
were used to study basophil function.
CFSE labeling and cell culture
PBMC were labeled with CFSE by incubating PBMC (2 × 107 cells/ml) in RPMI with 2.5
μM CFSE for 8 minutes at 37°C with gentle shaking, then washing excess dye away. CFSE-
labeled PBMC were then cultured in the presence of milk proteins (α-casein, β-casein, α-
lactalbumin, β-lactoglobulin (Sigma-Aldrich), each at a concentration of 12.5 μg/ml),
tetanus toxoid (TT, 0.5 μg/ml) or left unstimulated in RPMI-1640 containing gentamycin
and supplemented with 10% AB+ serum and glutamine. Cells were distributed in 48-well
flat-bottom plates, at a concentration of 1 × 106/800 μl medium per well. Some of the
cultures were also treated with rhIL2 (50 IU/ml). After 7 days of culture, PBMC were
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tcollected and stained with PE-conjugated anti-CD4 (RPA-T4; Biolegend), PerCP/Cy5.5-
conjugated anti-CD8 (SK1; Biolegend), APC-conjugated anti-CD25 (BC96; Biolegend) and
APC-eFluor 780-conjugated anti-CD3 (UCHT1; eBioscience). Some samples were also
stained with PerCP/Cy5.5-conjugated anti-CD279 (PD-1) (EH12.2H7; Biolegend), APC-
conjugated anti-CD152 (CTLA-4) (L3D10; Biolegend) and APC-Cy7-conjugated anti-HLA-
DR (L243; Biolegend).
Detection of cytokine production by flow cytometry
After 7 days of culture with milk proteins, PBMC were restimulated with phorbol myristate
acetate (PMA) (25 ng/ml), ionomycin (0.5 μg/ml) and monensin for 5 hours, then fixed and
permeabilized with BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences),
and stained with PE-conjugated anti-CD4 (RPA-T4, Biolegend), APC-conjugated anti–IL-4
(8D4-8; Biolegend) and Alexa Fluor 700- conjugated anti-IFN-γ (4S.B3; Biolegend). Some
cultures were also stained with APC-conjugated anti-IL-10 (JES3-19F1; BD Biosciences)
and anti-IL-13 (JES10-5A2; Biolegend). PBMC cultured in the presence of the same
antigens, but not restimulated with PMA and ionomycin were used as negative controls.
Detection of regulatory T cells by flow cytometry
After 7 days of culture with milk proteins, PBMC were harvested, fixed and permeabilized
with Foxp3 Staining Buffer kit (eBioscience), and stained with PE-conjugated anti-CD4
(RPA-T4, Biolegend) and APC-conjugated anti–FoxP3 (236A/E7; eBioscience).
Study of regulatory T cell function
CFSE-labeled PBMCs were cocultured in the presence of milk proteins and treated or not
with anti-IL-10 (JES3-9D7, 5 μg/ml; Biolegend) and/or anti-TGF-β (5 μg/ml) mAbs. In
another series of experiments, regulatory T cells and untouched CD4+ T cells were purified
from PBMC using the CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec). CD4+
CD25+ cells (1 or 5 × 104 cells) or CD4+ cells (1.5 or 7.5 × 104 cells) were then cocultured
with 2 × 105 baseline PBMC in 96-well plates in the presence of milk proteins. The
proliferation was measured as [3H]thymidine incorporation during the last 16 hours of a 6-
day culture.
Examination of basophil function
Basophil function was studied as previously described 49. Briefly, basophils, identified by
gating on at least 500 Live/DeadloCD3−CD16−CD20−CD56−CD66b−HLA-DR−CD123+
cells, were assessed by flow cytometry for changes in expression of CD203 and CD63.
Antibodies used were CD3 (UCHT1, Alexa 488), CD41a (96.2C1, Alexa 488), CD66b
(G10F5, Alexa 488), CD123 (7G3, Alexa 647) and HLA-DR (L243, Alexa 488), from BD
Bio sciences (San Jose, CA), and CD203c (NP4D6, purified) from BioLegend (San Diego,
CA). CD203c was custom-conjugated to Pacific Blue (Invitrogen) as per the manufacturer’s
protocol. Histamine released into culture supernatants was detected using standardized
ELISA methods in quadruplicate.
Prick skin testing
Skin prick tests were conducted via a standardized procedure by a trained, licensed specialist
in allergy, using allergens (milk, egg, cashew) from Greer Laboratories.
Determination of serum levels of milk-specific IgE and IgG4
Total milk allergen-specific IgE was quantified in sera collected at time points when patients
were not being treated with omalizumab using the ImmunoCAP System (Phadia,
Kalamazoo, MI). IgG4 anti-milk was assessed in sera using the UniCAP 100 (Phadia,
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tKalamazoo, MI) by separately measuring IgG4 antibody levels to the three principal milk
allergenic components (casein, α-lactalbumin and β-lactoglobulin). These were summed to
provide a measure in μg/ml of IgG4 anti-milk, since IgG anti-milk could not be directly
measured in serum using the milk-extract CAP reagent due to the high prevalence of BSA-
reactive IgG antibodies in many sera from healthy humans.
Statistics
For most comparisons, we used the paired t-test or 2 way anova for matched values. For
immunoglobulin levels (not distributed in a Gaussian manner), we used nonparametric
Wilcoxon tests. Differences were considered significant with P <0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Milk-induced CD4+ T cell proliferation is greatly reduced during the rush
desensitization phase
(a) Frozen PBMC, isolated from 5 milk allergic patients undergoing rush milk
desensitization, were thawed and labeled with CFSE, and cultured in the presence of tetanus
toxoid (TT) or milk proteins (MP) for 7 days. Cells were then collected, stained with anti-
CD4 mAb, and analyzed by flow cytometry. The number in each panel represents the
fraction of total CD4+ cells that are within the CFSElow CD4+ gate (antigen-specific
proliferating cells) on day 0. Mean CD4+ milk-specific proliferating cells=7.75%; mean
CD4+ tetanus specific cells=24.6%. Mean CD4+ proliferating cells without antigen=0.62%.
(b) Each line represents data for all 5 patients combined (solid line, milk protein (MP);
dashed line, tetanus toxoid (TT)). Data represent mean % antigen-specific cells (CFSElow
CD4+ cells) of total CD4+ cells, normalized to day 0 for each patient ± SEM, over the
course of the study. ** p < 0.01, *** p < 0.001 versus baseline and week 8, determined
using paired t-test. ° p < 0.05 versus TT response, determined using two-way ANOVA for
matched values with Bonferroni’s post hoc test.
(c) Each line represents data for an individual patient, of % milk-specific CFSElow CD4+
cells of total CD4+ cells, normalized to day 0 for each patient, over the course of the study.
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tFigure 2. Milk specific Foxp3+ T cells are not detected during the milk desensitization
(a–c) CFSE-labeled PBMC isolated from 5 milk allergic patients undergoing milk
desensitization were cultured in the presence of milk proteins for 7 days. Cells were then
collected, fixed and permeabilized, stained with anti-CD4 and anti–Foxp3, and analyzed by
flow cytometry.
(a–b) Figures represent combined percentages of CD4+ Foxp3+ cells of total cells
normalized to day 0. Data represent mean ± SEM.
(a) Normalized CD4+ CFSElow cells (proliferating cells, representing milk-specific TReg
cells).
(b) Normalized CD4+ CFSEhigh cells (nonproliferating cells, representing natural TReg
cells).
(c) Individual dot plots of flow cytometry analysis are shown. CD4+CFSElow T cells (left
panels) represent milk-specific TReg cells, which did not increase over time. CD4+CFSEhigh
T cells (right panels) represent natural TReg cells, which did not change over time.
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tFigure 3. Functional regulatory T cells are not detected during the milk desensitization
(a–b) CFSE-labeled PBMC isolated from 5 patients undergoing milk desensitization were
cultured in the presence of milk (MP) for 7 days. Cells were then collected, stained with
anti-CD4 mAb, and analyzed by flow cytometry.
(a) Frozen samples from multiple time points were thawed and cultured with or without
anti-IL-10 mAb and milk proteins. Percentages of the milk-specific cell populations
(CFSElow) within the CD4+ gate are shown. Results with and without anti-IL-10 mAb
overlap, indicating an absence of IL-10 mediated suppression.
(b) PBMC from week 12 were cultured with or without anti-IL-10, anti-TGF-β mAb or both
and compared to baseline PBMC. Figures represent percentages of the milk-specific cell
populations (CFSElow) within the CD4+ gate. No increase in proliferation was observed with
the mAbs, indicating an absence of IL-10 or TGF-β mediated suppression.
(c) CD4+ T cells and regulatory T cells were purified from week 12 and week 14 PBMC,
respectively. 1× 104 (+) or 5 × 104 (++) CD4+ CD25+ cells, or 1.5 × 104 (+) or 7.5 × 104 (+
+) CD4+ cells were then cocultured with 2 × 105 baseline PBMC in the presence of milk
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tproteins. The proliferation was measured as [3H]thymidine incorporation during the last 16
hours of a 6-day culture.
Bedoret et al. Page 15
Mucosal Immunol. Author manuscript; available in PMC 2012 November 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 4. Evidence of milk-specific CD4+ T cell anergy
(a). PBMC were isolated from week 12 samples of 5 milk allergic patients undergoing milk
desensitization protocol, labeled with CFSE, cultured in the presence of milk proteins (MP)
for 7 days and treated with or without IL-2. Cells were then collected and stained with anti-
CD4 mAb. Proliferation was analyzed by flow cytometry and compared to PBMC
proliferation from baseline samples. Figure shows percentages of the milk-specific cells
(CFSElow) within the CD4+ gate as mean ± SEM for 5 patients. ** p < 0.01, *** p < 0.001.
Significance was determined using paired t-test.
(b–d). Phenotype of the milk specific CD4+ T cells during desensitization. CFSE-labeled
PBMC isolated from all 5 of the milk allergic patients undergoing milk desensitization were
cultured in the presence of milk proteins for 7 days, then analyzed by flow cytometry.
(b) Data represent CD25 expression (mean CD25 MFI (mean fluorescence intensity)) by
milk specific (CD4+ CFSElow) cells ± SEM for the 5 patients evaluated, normalized to
results on day 0.
(c) Solid line represents CD25 expression (mean MFI) for milk specific cells from the 4
patients who were desensitized and who passed the DBPCFC, normalized to results on day
0. Dashed line represents CD25 expression (MFI) by milk specific cells from patient #3,
who was only partially desensitized, normalized to results on day 0. * p < 0.05 versus
baseline and week 8, using paired t-test.
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t(d) Each line represents CD25 expression (MFI) on milk specific cells from each patient
normalized to results on day 0. Patient #3 was only partially desensitized.
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tFigure 5. Evidence for immune deviation during milk desensitization
(a–c) PBMC isolated from 5 milk allergic patients undergoing milk desensitization, labeled
with CFSE, and cultured in the presence of antigens for 7 days, were restimulated with PMA
and ionomycin in the presence of monensin for 5 h. Cytokine production was then assessed
using intracellular IL-4, IFN-γ and IL-13 staining.
(a) Data for all 5 patients. IFN-γ/IL-4 production ratio for the antigen-specific (CFSElow)
CD4+ T cells, normalized to day 0 is shown (mean ± SEM).
Bedoret et al. Page 18
Mucosal Immunol. Author manuscript; available in PMC 2012 November 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(b) Solid line represents data from (A), for desensitized patients (patients #1, 2, 4 and 5),
and dotted line represents data from (A), for the partially desensitized patient (patient #3). *
p < 0.05 versus baseline and week 8, using paired t-test.
(c) Each line represents data for an individual patient, representing IFN-γ/IL-4 production
ratio by the antigen-specific CD4+ T cells, normalized to day 0.
(d) IL-13 production was also assessed in CD4+ T cells from patient #5. Data represents
IFN-γ/IL-13 production by milk-specific CD4+ T cells.
(e–f) Serum milk-specific IgE (e) and IgG4 (f) levels were determined for the 10 patients
who completed the study. Points represent data from different individuals and bars show
mean values ± SEM. * p < 0.05, ** p < 0.01 versus baseline, determined using
nonparametric Wilcoxon matched-pairs test.
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tFigure 6. Milk skin test reactivity and in vitro basophil activation are reduced by oral milk
desensitization
(a) Skin prick test wheal with cow’s milk allergen extract (n=10) was reduced at week 52
compared to week 0. ** P < 0.01 determined using paired t-test. ° patient #3, who was slow
to become desensitized.
(b) Skin prick test wheal with cashew or ovalbumin did not change, comparing week 0 and
week 52 time points in 4 patients known to have those allergies.
(c) Basophils in whole blood, taken on day 0, but not subsequently, when stimulated ex vivo
for 20 minutes with cow’s milk (CM), were activated, as assessed by expression of CD203c,
CD63 and histamine release (n=5). Treatment with vehicle/glycerine showed no shift in
CD203c or CD63 expression (data not shown). MFI = median fluorescence intensity.
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t(d) Basophil activation with cashew or ovalbumin was blocked by in vivo treatment with
omalizumab, as assessed on weeks 8, 9, 10 and 16. Prior to and after omalizumab treatment,
basophil activation with cashew or ovalbumin was robust, as assessed by expression of
CD203c, CD63 and histamine release.
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